The observed effect was robust in sensitivity analyses and independent of fibrate dose .
The present meta- analysis suggests that fibrate therapy increases circulating levels of adiponectin .
BACKGROUND Several lines of evidence have indicated the insulin-sensitizing , anti-diabetic and anti-atherosclerotic properties of adiponectin , as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes .
Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy , but the findings have not been conclusive .
OBJECTIVE To systematic ally review and meta-analyze available evidence from r and omized placebo-controlled trials ( RCTs ) on the impact of fibrate therapy on circulating levels of adiponectin .
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
BACKGROUND Development of insulin resistance ( IR ) may be important in the pathogenesis of both metabolic syndrome and type 2 diabetes mellitus . Few data are available regarding the short-term efficacy of the peroxisome proliferator-activated receptor lig and bezafibrate on IR , and its long-term effect is unknown . The present analysis aim ed to investigate the effect of bezafibrate on IR in patients with coronary artery disease enrolled in the Bezafibrate Infa rct ion Prevention Study . METHODS Metabolic and inflammatory parameters were analyzed from stored frozen plasma sample s obtained from patients who completed a 2-year , r and omized , double-blind , placebo-controlled study . The homeostatic indexes of IR ( HOMA-IRs ) were calculated according to the homeostasis model of assessment . RESULTS Both the patients taking bezafibrate ( n = 1262 ) and those taking placebo ( n = 1242 ) displayed similar baseline characteristics . The HOMA-IRs significantly correlated at baseline and during follow-up with glucose ( r = 0.35 and 0.31 , respectively ) and triglycerides ( r = 0.16 and 0.19 , respectively ) . In a subgroup of 351 patients with diabetes , HOMA-IR at baseline was 88 % higher than in their counterparts with normal glucose levels ( P<.001 ) . In the placebo group , during follow-up there was a significant 34.4 % rise in HOMA-IR . In contrast , in the bezafibrate group there was only a nonsignificant 6.6 % change in HOMA-IR . The intergroup differences in percentage changes of HOMA-IR were in favor of bezafibrate ( P<.001 ) . CONCLUSIONS In patients with coronary artery disease enrolled in our study , as represented by the placebo group , HOMA-IR increased over time . During the 2 years of the follow-up , bezafibrate significantly attenuated this process
The observed effect was robust in sensitivity analyses and independent of fibrate dose .
The present meta- analysis suggests that fibrate therapy increases circulating levels of adiponectin .
BACKGROUND Several lines of evidence have indicated the insulin-sensitizing , anti-diabetic and anti-atherosclerotic properties of adiponectin , as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes .
Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy , but the findings have not been conclusive .
OBJECTIVE To systematic ally review and meta-analyze available evidence from r and omized placebo-controlled trials ( RCTs ) on the impact of fibrate therapy on circulating levels of adiponectin .